// App-Quantinova.ai

: Long-term efficacy and safety of once-monthly pasireotide in patients with Cushing's disease: A Phase III extension study

Researchers

Presenter

  • Maria Fleseriu

Principal Investigators

  • Stephan Petersenn

  • Beverly M K Biller

  • Pinar Kadioglu

  • Christophe De Block

  • Guy T’Sjoen

  • Marie C Vantyghem

  • Libuse Tauchmanova

  • Shoba Ravichandran

  • Michael Roughton

  • Andre Lacroix

  • John Newell-Price

Medical Centers

  • Oregon Health and Science University, Portland, Oregon, United States

  • ENDOC Center for Endocrine Tumors, Hamburg, Germany

  • Massachusetts General Hospital, Boston, MA, United States

  • Pituitary Center, Istanbul University, Istanbul, Turkey

  • Department of Endocrinology, Diabetology and Metabolism, Antwerp University Hospital, Antwerp, Belgium

  • Department of Endocrinology and Center for Sexology and Gender, Ghent University Hospital, Ghent, Belgium

  • Endocrinology, Diabetology and Metabolism, CHU Lille, Lille, France

  • Novartis AG, Basel, Switzerland

  • Novartis Pharmaceutical Corporation, East Hanover, NJ

  • Centre Hospitalier de LUniversite de Montreal (CHUM), Montreal, QC, Canada

  • CIMA, University of Sheffield, Sheffield, UK

Locations

  • United States

  • Germany

  • Turkey

  • Belgium

  • France

  • Switzerland

  • Canada

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

Disease

  • N/A

Biomarkers

  • Cortisol

Drug/Treatment

  • Pasireotide

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved